Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.44 |
| ▸ | NPY1R | P25929 | 6/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 4/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948383 | 0.95 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL29889146 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL29461986 | 0.92 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL30475878 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL29913275 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30216757 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL29482469 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30475873 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30676227 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKLK7 | |
| SCHEMBL29889197 | 0.90 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NPY4R 4433/4885NPY1R 3079/4885NPY2R 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.